Stockscreener 앱 받기
8.41
11.19%
-1.06
시간 외 거래:
8.25
-0.16
-1.90%
전일 마감가:
$9.47
열려 있는:
$9.38
하루 거래량:
44,368
Relative Volume:
0.49
시가총액:
$222.85M
수익:
-
순이익/손실:
$-35.46M
주가수익비율:
-19.94
EPS:
-0.4218
순현금흐름:
$-34.00M
1주 성능:
-14.10%
1개월 성능:
-38.93%
6개월 성능:
-50.12%
1년 성능:
+0.00%
1일 변동 폭
$8.31
$9.40
1주일 범위
$8.31
$9.73
52주 변동 폭
$8.31
$22.00
Contineum Therapeutics Inc Stock (CTNM) Company Profile
명칭
Contineum Therapeutics Inc
전화
(858) 333-5280
주소
3565 GENERAL ATOMICS COURT, SUITE 200, SAN DIEGO
CTNM을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CTNM
Contineum Therapeutics Inc
|
8.41 | 222.85M | 0 | -35.46M | -34.00M | -0.4218 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.32 | 122.13B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
710.00 | 78.30B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
646.64 | 39.73B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
276.19 | 35.50B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.61 | 28.47B | 3.30B | -501.07M | 1.03B | -2.1146 |
Contineum Therapeutics Inc Stock (CTNM) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-10-22 | 개시 | Robert W. Baird | Outperform |
| 2024-04-30 | 개시 | Morgan Stanley | Overweight |
| 2024-04-30 | 개시 | RBC Capital Mkts | Outperform |
| 2024-04-30 | 개시 | Stifel | Buy |
Contineum Therapeutics Inc 주식(CTNM)의 최신 뉴스
Contineum Therapeutics (CTNM) Projected to Post Quarterly Earnings on Wednesday - Defense World
(CTNM) Investment Analysis and Advice - Stock Traders Daily
Pulmonary Fibrosis Clinical Trial Pipeline Appears Robust With 110+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - GlobeNewswire Inc.
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Contineum Therapeutics, Inc.'s (NASDAQ:CTNM) 12% loss last week hit both individual investors who own 37% as well as institutions - Simply Wall St
New Oriental Education, Walgreens And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Benzinga
Contineum concludes enrolment in Phase II multiple sclerosis therapy trial - MSN
Enrollment complete in Phase 2 trial of remyelination therapy for RRMS - Multiple Sclerosis News Today
Contineum Therapeutics (NASDAQ:CTNM) Earns “Outperform” Rating from Royal Bank of Canada - Defense World
Contineum Therapeutics' (CTNM) "Outperform" Rating Reaffirmed at Royal Bank of Canada - MarketBeat
Ionis to present at 43rd Annual J.P. Morgan Healthcare Conference - Quantisnow
Contineum Therapeutics, Inc. Completes Enrollment in Phase 2 PIPE-307 Vista Trial for the Treatment of Relapsing-Remitting Multiple Sclerosis - Marketscreener.com
Barclays PLC Raises Stock Position in Contineum Therapeutics, Inc. (NASDAQ:CTNM) - Defense World
Geode Capital Management LLC Sells 27,745 Shares of Contineum Therapeutics, Inc. (NASDAQ:CTNM) - Defense World
Contineum Therapeutics Completes Enrollment in Phase 2 PIPE-307 VISTA Trial for the Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS) - Business Wire
RAPT Therapeutics Names Lori Lyons-Williams Chair of the Company's Board of Directors - The Manila Times
State Street Corp Raises Stock Holdings in Contineum Therapeutics, Inc. (NASDAQ:CTNM) - Defense World
Contineum Therapeutics, Inc. (NASDAQ:CTNM) Short Interest Update - MarketBeat
When the Price of (CTNM) Talks, People Listen - Stock Traders Daily
Director Hayden Michael R bought $181,079 worth of shares (5,000 units at $36.22), increasing direct ownership by 17% to 35,219 units (SEC Form 4) - Quantisnow
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Quantisnow
(CTNM) Proactive Strategies - Stock Traders Daily
Charles Schwab Investment Management Inc. Sells 8,477 Shares of Contineum Therapeutics, Inc. (NASDAQ:CTNM) - Defense World
Franklin Resources Inc. Acquires 820,542 Shares of Contineum Therapeutics, Inc. (NASDAQ:CTNM) - MarketBeat
BNP Paribas Financial Markets Acquires 829 Shares of Farmers National Banc Corp. (NASDAQ:FMNB) - Defense World
BNP Paribas Financial Markets Raises Holdings in Kyverna Therapeutics, Inc. (NASDAQ:KYTX) - Defense World
BNP Paribas Financial Markets Has $129,000 Stock Holdings in Contineum Therapeutics, Inc. (NASDAQ:CTNM) - Defense World
Contineum Therapeutics Initiates Patient Dosing in Phase 1b Positron Emission Tomography (PET) Trial of PIPE-791 - Business Wire
Contineum Therapeutics' SWOT analysis: biotech stock shows promise amid risks - Investing.com
Adobe, Keros Therapeutics, Lovesac And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Benzinga
Why DBV Technologies Shares Are Trading Higher By Around 37%; Here Are 20 Stocks Moving Premarket - Benzinga
Fmr LLC Raises Stake in Contineum Therapeutics, Inc. (NASDAQ:CTNM) - MarketBeat
(CTNM) On The My Stocks Page - Stock Traders Daily
Contineum Therapeutics, Inc. (NASDAQ:CTNM) Shares Sold by Suvretta Capital Management LLC - MarketBeat
Contineum Therapeutics chief scientific officer sells stock worth $16,177 By Investing.com - Investing.com Nigeria
Contineum Therapeutics chief scientific officer sells stock worth $16,177 - Investing.com India
Avidity Biosciences to Participate in Upcoming Investor Conference - Quantisnow
Contineum Therapeutics to Attend the 7th Annual Evercore HealthCONx Conference - BioSpace
Contineum Therapeutics chief scientific officer sells $101,420 in stock By Investing.com - Investing.com Australia
Contineum Therapeutics chief scientific officer sells $101,420 in stock - Investing.com
Contineum Therapeutics Expands Clinical Development of PIPE-791 With FDA Authorization of Its Investigational New Drug (IND) Application for Chronic Pain - BioSpace
(CTNM) Trading Signals - Stock Traders Daily
Sectoral Asset Management Inc's Strategic Acquisition in Contine - GuruFocus.com
75+ Key Companies Charting New Frontiers in Multiple Sclerosis Therapeutic Space | DelveInsight - The Malaysian Reserve
Here's Why We're Not At All Concerned With Contineum Therapeutics' (NASDAQ:CTNM) Cash Burn Situation - Yahoo Finance
Contineum Therapeutics to Attend Upcoming Investor Conferences - BioSpace
Contineum Therapeutics Announces Financial Results for the Quarter Ended September 30, 2024 - Defense World
Contineum Therapeutics' SWOT analysis: promising pipeline drives stock outlook - Investing.com India
Contineum Therapeutics Inc (CTNM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Contineum Therapeutics Inc 주식 (CTNM) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Lorrain Daniel S. | Chief Scientific Officer |
Nov 18 '24 |
Sale |
16.38 |
6,190 |
101,421 |
169,572 |
1.09%
자본화:
|
볼륨(24시간):